Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin
暂无分享,去创建一个
[1] Y. Sugiyama,et al. Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11 , 2005, Hepatology.
[2] E. Wang,et al. Fluorescent Substrates of Sister-P-Glycoprotein (BSEP) Evaluated as Markers of Active Transport and Inhibition: Evidence for Contingent Unequal Binding Sites , 2003, Pharmaceutical Research.
[3] Richard J. Thompson,et al. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.
[4] P. Meier,et al. Functional expression of the canalicular bile salt export pump of human liver. , 2002, Gastroenterology.
[5] Ronald T. Borchardt,et al. Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa? , 2002, Pharmaceutical Research.
[6] R. Batey,et al. Cholestasis associated with the use of pravastatin sodium , 2002, The Medical journal of Australia.
[7] A. Guo,et al. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[8] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[9] T. Abe,et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.
[10] P. Meier,et al. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system , 2001, Hepatology.
[11] Y. Sugiyama,et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[12] W. Mück. Clinical Pharmacokinetics of Cerivastatin , 2000, Clinical pharmacokinetics.
[13] P. Meier,et al. Transport function and hepatocellular localization of mrp6 in rat liver. , 2000, Molecular pharmacology.
[14] T. Uchiumi,et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.
[15] J. Jiménez-Alonso,et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. , 1999, Archives of internal medicine.
[16] I. Hirsch,et al. Pulmonary edema associated with troglitazone therapy. , 1999, Archives of internal medicine.
[17] P. Neuvonen,et al. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.
[18] H. Yawo,et al. Pravastatin, an HMG-CoA Reductase Inhibitor, Is Transported by Rat Organic Anion Transporting Polypeptide, oatp2 , 1999, Pharmaceutical Research.
[19] Hiroshi Suzuki,et al. Characterization of the Transport Properties of Cloned Rat Multidrug Resistance-associated Protein 3 (MRP3)* , 1999, The Journal of Biological Chemistry.
[20] H. Fujino,et al. Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (4) : Interspecies Variation in Laboratory Animals and Humans , 1999 .
[21] P. Neuvonen,et al. Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.
[22] Richard J. Thompson,et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.
[23] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[24] C. Spurr,et al. Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone , 1998, Annals of Internal Medicine.
[25] P. Meier,et al. The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.
[26] Y. Sugiyama,et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[27] H. Lennernäs,et al. Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.
[28] M. Yamazaki,et al. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. , 1996, Biopharmaceutics & drug disposition.
[29] Y. Adachi,et al. Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradient , 1996, Journal of gastroenterology and hepatology.
[30] P. Borst,et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[31] C. Goresky,et al. Enalaprilat handling by the kidney: barrier-limited cell entry. , 1992, The American journal of physiology.
[32] P. Opolon,et al. Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man , 1992, Digestive Diseases and Sciences.
[33] M. Campanini,et al. Acute cholestatic hepatitis during simvastatin administration. , 1991, Recenti progressi in medicina.
[34] Gudrun Wacker. Similarities and Differences , 2005 .
[35] Bruno Stieger,et al. Enterohepatic bile salt transporters in normal physiology and liver disease. , 2004, Gastroenterology.
[36] Ronald T. Borchardt,et al. Are MDCK Cells Transfected with the Human MRP2 Gene a Good Model of the Human Intestinal Mucosa? , 2004, Pharmaceutical Research.
[37] R. Kim,et al. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. , 2000, Molecular pharmacology.
[38] Y. Sugiyama,et al. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). , 2000, The Journal of pharmacology and experimental therapeutics.
[39] Y. Sugiyama,et al. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. , 1993, The American journal of physiology.
[40] T Nakagawa,et al. A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.